PolyPid's D-PLEX100 MAA validated by EMA for SSI prevention

The EMA has accepted PolyPid's marketing authorisation application for D-PLEX100, which also faces an FDA PDUFA date of 28 November 2026.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A white medical device displaying a blue waveform on its screen with a connected tube sits on a desk in a brightly lit modern office with a large window, a potted plant, an office chair, and books on a shelf.

PolyPid has received confirmation that the European Medicines Agency has validated its Marketing Authorisation Application for D-PLEX100, the Israeli company's controlled-release antibiotic candidate for the prevention of surgical site infections following abdominal surgery. Validation, which confirms the submission is complete and formally initiates the EMA review, was granted just over two weeks after PolyPid lodged the application on 14 September 2026.

The MAA was submitted under the Centralised Procedure on the basis of therapeutic innovation, a route that, if successful, yields a single marketing authorisation valid across all EU member states. The EMA's Committee for Medicinal Products for Human Use will now conduct the formal scientific assessment. PolyPid had held preparatory meetings with the EMA Rapporteur and Co-Rapporteur during the second quarter of 2026, suggesting the dossier had already been pre-shaped to committee expectations.

Clinical evidence and mechanism

D-PLEX100 combines doxycycline, a broad-spectrum antibiotic, with PolyPid's Kynatrix delivery platform. The device is applied directly to the surgical site and is designed to release the drug continuously at high local concentrations for 30 days, with the aim of reducing both standard and antibiotic-resistant SSIs without generating systemic exposure.

The MAA is underpinned by the Phase 3 SHIELD II trial, which met its primary endpoint and all key secondary endpoints, reporting a 60% relative risk reduction in SSI incidence compared with standard of care (p=0.0013). That dataset also supported the company's US regulatory filing: the FDA accepted the New Drug Application and granted Priority Review, with a PDUFA goal date of 28 November 2026. D-PLEX100 holds FDA Breakthrough Therapy Designation for the prevention of SSIs in elective colorectal surgery.

Dikla Czaczkes Akselbrad, chief executive of PolyPid, said the validated MAA represented "another important step toward potential commercialisation in major global markets" and pointed to strategic opportunities in the European SSI segment, where the company retains its own commercial rights. Outside the US and Canada, PolyPid holds commercialisation rights directly; in North America it has partnered with Azurity Pharmaceuticals.

Market context and competitive landscape

Surgical site infections represent a substantial clinical and economic burden across European health systems. SSIs are among the most common hospital-acquired complications following abdominal procedures, and rising rates of antibiotic-resistant pathogens have increased pressure on surgical teams to identify adjunctive prevention strategies beyond systemic prophylaxis. Current standard of care relies primarily on pre-operative intravenous antibiotics, wound irrigation, and aseptic technique, with limited approved options for prolonged local prophylaxis.

D-PLEX100's local-delivery approach positions it in a niche that few products currently occupy, though a number of academic and commercial groups have explored antibiotic-impregnated materials and biodegradable matrices for similar indications. If approved, the product would be among the first controlled-release site-specific antibiotic prophylaxis agents to reach the EU market for open abdominal surgery, giving PolyPid a potential first-mover window before follow-on entrants can progress through late-stage trials.

The dual-track regulatory situation, with an FDA PDUFA date less than two months away and EMA review now formally under way, means PolyPid could face significant near-term catalysts on both sides of the Atlantic. The PDUFA date in particular will draw close investor scrutiny, given that FDA decisions on Priority Review applications typically arrive on or before the goal date. A positive US outcome would likely strengthen the EMA dossier's commercial prospects and may prompt partnership conversations for the European territory.

Sector

Topic

Geography